Drug Discovery and Development Solutions for Obesity

Our In Vitro Efficacy Testing Service accelerates obesity drug discovery by offering robust, sensitive screening and characterization platforms targeting key metabolic pathways and receptors, including GLP-1R, GIPR, and others. Utilizing diverse methodologies—such as cell-based, biochemical, biophysical, and binding assays (e.g., HTRF, FRET, luciferase, ELISA, radioligand displacement)—we deliver comprehensive data on compound potency, efficacy, and selectivity. Key pharmacological parameters (EC-50, IC-50, Ki, Kd) are precisely measured in physiologically relevant matrices, supporting informed candidate selection and lead optimization. Our expertise ensures actionable insights for effective anti-obesity therapeutic development and streamlined progression through early-stage screening.

Protheragen’s Animal Model Development Service for obesity offers comprehensive in vivo solutions using over 400 validated models across 15 species and 77 strains. We provide diet-induced, genetic, chemically-induced, and surgical models tailored to client research needs. Our methodologies include customized diets, genetic engineering, chemical induction, and advanced surgical techniques. Key endpoints measured include body weight, metabolic parameters, histopathology, and molecular biomarkers. with advanced analytics such as omics and imaging, rigorous quality control, and expert scientific guidance, we ensure robust, reproducible, and translational data to accelerate the development of effective anti-obesity therapeutics.

Our PK/PD research service for obesity integrates advanced analytical platforms, diverse administration routes, and comprehensive compartment analysis across multiple biological matrices. Utilizing physiologically relevant animal models, we provide precise quantification of drug candidates and biomarkers, enabling robust ADME characterization, dose optimization, and translational biomarker discovery. Our expertise supports the evaluation of safety, efficacy, and interspecies scaling, ensuring actionable data for each development stage. By translating preclinical findings into clinically meaningful insights, we accelerate the development of safe and effective obesity therapeutics, offering end-to-end support to optimize dosing strategies and maximize clinical success for our partners.

Protheragen’s Toxicity Assessment Service for obesity therapeutics delivers comprehensive in vivo safety evaluations, encompassing acute, chronic, organ-specific, behavioral, and metabolic toxicity studies. Utilizing validated animal models and advanced analytical technologies, we rigorously assess key safety parameters such as hepatotoxicity, neurobehavioral effects, and metabolic disturbances. Our GLP-compliant protocols and robust data analytics ensure high-quality, regulatory-ready results. By integrating metabolic phenotyping and specialized endpoints, we address the unique safety challenges of obesity drug development, providing clients with actionable insights to de-risk candidate selection and accelerate regulatory progression, ultimately supporting the advancement of safe and effective obesity treatments.

Protheragen offers biomarker analysis services supporting obesity drug discovery and preclinical research. We utilize advanced multi-omics approaches—integrating genomics, transcriptomics, proteomics, and metabolomics—to explore and screen molecular candidates with potential as obesity-related biomarkers. Our platforms enable evaluation of proteins, peptides, genetic variants, and metabolites using immunoassays, mass spectrometry, flow cytometry, and molecular diagnostics. Through systematic screening, literature mining, and experimental investigation, we assess candidate relevance and analytical performance. Our technical expertise facilitates comprehensive exploratory studies, providing objective data to inform mechanistic understanding and therapeutic strategies. All research is strictly preclinical, with an emphasis on scientific rigor and cautious interpretation.